Claims
- 1. A method of treating malignant diseases in mammals, which comprises administering to a mammal suffering therewith a therapeutically effective amount of a compound represented by the formula: ##STR7## wherein: Z is hydrogen or --C(O)R, where R is lower alkyl or aryl; a a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1 wherein Z is hydrogen.
- 3. The method of claim 1 comprising administering an antineoplastic amount of said compound or pharmaceutically acceptable salt thereof.
- 4. The method of claim 2 comprising administering an antineoplastic amount of said compound or pharmaceutically acceptable salt thereof.
- 5. The method of claim 1 wherein said malignant disease is selected from the group: malignancies of lympho-reticular origin, and solid tumors.
- 6. The method of claim 5 wherein: said malignancies of lympho-reticular origin are selected from the group:
- leukemias and lymphomas, including L1210 leukemia and X-5563 plastmacytoma,
- human T- and B-lymphocytic and promonocytic cell line malignancies,
- Burkitt lymphoma cells and other EBV-transformed B-lymphocytes, including DAUDI, CESS, SKW and malignancies corresponding thereto in humans, and T-lymphomas and leukemias including MOLT-4 and malignancies corresponding thereto in humans, and
- lymphomas resulting from Epstein-Barr viral infections in allograft recipients; and
- said solid tumors are selected from the group:
- RIF-1 radiation-induced sarcoma, SCCVII squamous carcinoma, DIM-16 and DIM-20 mammary carcinoma, 3LL-CK Lewis lung carcinoma, NF sarcoma, sarcoma 180, and solid tumors corresponding thereto in humans.
- 7. The method of claim 2 wherein said malignant disease is selected from the group: malignancies of lympho-reticular origin, and solid tumors.
- 8. The method of claim 7 wherein: said malignancies of lympho-reticular origin are selected from the group:
- leukemias and lymphomas, including L1210 leukemia and X-5563 plasmacytoma,
- human T- and B-lymphocytic and promonocytic cell line malignancies,
- Burkitt lymphoma cells and other EBV-transformed B-lymphocytes, including DAUDI, CESS, SKW and malignancies corresponding thereto in humans, and T-lymphomas and leukemias including MOLT-4 and malignancies corresponding thereto in humans, and
- lyphomas resulting from Epstein-Barr viral infections in allograft recipients; and
- said solid tumors are selected from the group:
- RIF-1 radiation-induced sarcoma, SCCVII squamous carcinoma, DIM-16 and DIM-20 mammary carcinoma, 3LL-CK Lewis lung carcinoma, NF sarcoma, sarcoma 180, and solid tumors corresponding thereto in humans.
Parent Case Info
This is a division of pending application Ser. No. 093,459, now U.S. Pat. No. 4,808,592 filed Sept. 4, 1987, which in turn is a division of application Ser. No. 008,717 filed Jan. 30, 1987, now U.S. Pat. No. 4,753,935, issued June 28, 1988, incorporated herein by reference.
US Referenced Citations (7)
Foreign Referenced Citations (8)
Number |
Date |
Country |
86860 |
Nov 1973 |
JPX |
86861 |
Nov 1973 |
JPX |
57-024380 |
Feb 1982 |
JPX |
57-183776 |
Nov 1982 |
JPX |
57-183777 |
Nov 1982 |
JPX |
1157100 |
Jul 1969 |
GBX |
1261060 |
Jan 1972 |
GBX |
2117238 |
Oct 1983 |
GBX |
Non-Patent Literature Citations (4)
Entry |
"Antitumor Activity of Derivatives of Mycophenolic Acid", Suzuki, et al., J. Antibiotics, 29(3), 275-285, 1975. |
"Carbamoyl Mycophenolic Acid Ethylester, An Oral Antitumor Agent", Suzuki, et al., J. Antibiotics, 29(3), 286-291, 1975. |
"Antitumor and Immunosuppressive Effects of Mycophenolic Acid", Ohsugi, et al., Cancer Research, 36, 2923-2927, 1976. |
"A Gastroprotective Anti-Inflammatory Agent: The .beta.-Morpholinoethyl Ester of Niflumic Acid (Morniflumate)", Schiantarelli, et al., Agents and Actions, 14(2), 1984. |
Divisions (2)
|
Number |
Date |
Country |
Parent |
93459 |
Sep 1987 |
|
Parent |
8717 |
Jan 1987 |
|